Rvl Pharmaceuticals Plc (RVLP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2022 | 12-2021 | 12-2020 | 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -51,692 | -64,920 | -79,589 | -270,901 | -109,681 |
| Depreciation Amortization | 16,748 | 17,661 | 94,478 | 340,762 | 185,794 |
| Income taxes - deferred | -90 | -194 | -1,156 | -26,794 | -15,513 |
| Accounts receivable | -898 | 7,108 | 17,496 | 12,674 | -17,041 |
| Accounts payable and accrued liabilities | -1,370 | -134 | -1,723 | -16,375 | -11,326 |
| Other Working Capital | 4,387 | -7,463 | -1,857 | -15,778 | -25,857 |
| Other Operating Activity | -4,895 | -6,790 | -10,059 | 9,979 | 31,182 |
| Operating Cash Flow | $-37,810 | $-54,732 | $17,590 | $33,567 | $37,558 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -752 | -1,782 | -3,134 | -3,946 | -4,134 |
| Net Acquisitions | 878 | 90 | 50 | -74 | N/A |
| Other Investing Activity | 0 | 118,145 | 0 | 0 | 0 |
| Investing Cash Flow | $126 | $116,453 | $-3,084 | $-4,020 | $-4,134 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 20,810 | 55,112 | N/A | 1,314 | 2,745 |
| Debt Repayment | -2,709 | -222,306 | -50,127 | -3,218 | -57,223 |
| Common Stock Issued | 23,825 | 32,647 | 62,659 | N/A | 58,084 |
| Common Stock Repurchased | N/A | N/A | -8,101 | -2,787 | 0 |
| Other Financing Activity | -143 | -783 | -749 | 0 | -2 |
| Financing Cash Flow | $41,783 | $-135,330 | $3,682 | $-4,691 | $3,604 |
| Exchange Rate Effect | N/A | N/A | N/A | 175 | -938 |
| Beginning Cash Position | 40,444 | 114,053 | 95,865 | 70,834 | 34,744 |
| End Cash Position | 44,543 | 40,444 | 114,053 | 95,865 | 70,834 |
| Net Cash Flow | $4,099 | $-73,609 | $18,188 | $25,031 | $36,090 |
| Free Cash Flow | |||||
| Operating Cash Flow | -37,810 | -54,732 | 17,590 | 33,567 | 37,558 |
| Capital Expenditure | -752 | -1,782 | -2,920 | -3,963 | -4,144 |
| Free Cash Flow | -38,562 | -56,514 | 14,670 | 29,604 | 33,414 |